1. Home
  2. OP vs VRAX Comparison

OP vs VRAX Comparison

Compare OP & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OP
  • VRAX
  • Stock Information
  • Founded
  • OP 2021
  • VRAX 2013
  • Country
  • OP Greece
  • VRAX United Kingdom
  • Employees
  • OP 106
  • VRAX N/A
  • Industry
  • OP
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • OP
  • VRAX Health Care
  • Exchange
  • OP Nasdaq
  • VRAX Nasdaq
  • Market Cap
  • OP 8.3M
  • VRAX 7.3M
  • IPO Year
  • OP N/A
  • VRAX 2022
  • Fundamental
  • Price
  • OP $1.11
  • VRAX $1.90
  • Analyst Decision
  • OP
  • VRAX
  • Analyst Count
  • OP 0
  • VRAX 0
  • Target Price
  • OP N/A
  • VRAX N/A
  • AVG Volume (30 Days)
  • OP 11.3K
  • VRAX 282.7K
  • Earning Date
  • OP 04-10-2025
  • VRAX 02-05-2025
  • Dividend Yield
  • OP N/A
  • VRAX N/A
  • EPS Growth
  • OP N/A
  • VRAX N/A
  • EPS
  • OP N/A
  • VRAX N/A
  • Revenue
  • OP $25,729,000.00
  • VRAX $84,872.00
  • Revenue This Year
  • OP N/A
  • VRAX $5,169.18
  • Revenue Next Year
  • OP N/A
  • VRAX $66.97
  • P/E Ratio
  • OP N/A
  • VRAX N/A
  • Revenue Growth
  • OP 36.33
  • VRAX 7.03
  • 52 Week Low
  • OP $1.02
  • VRAX $0.60
  • 52 Week High
  • OP $3.15
  • VRAX $9.00
  • Technical
  • Relative Strength Index (RSI)
  • OP 39.14
  • VRAX 49.13
  • Support Level
  • OP $1.11
  • VRAX $1.58
  • Resistance Level
  • OP $1.18
  • VRAX $2.10
  • Average True Range (ATR)
  • OP 0.04
  • VRAX 0.25
  • MACD
  • OP 0.00
  • VRAX 0.01
  • Stochastic Oscillator
  • OP 3.50
  • VRAX 47.88

About OP OceanPal Inc.

OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Share on Social Networks: